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ABSTRACT
Objective: This article compares the effect of interferon alfa plus cytarabine (IFN-
alfa  Ara-C) versus IFN-alfa alone on the chronic phase of chronic myelogenous leukemia.
Methods: Electronic searches were performed in the Cochrane Central Register
of Controlled Trials, PubMed, EMBASE, Chinese Biomedical Database, China Jour-
nal Full-text Database, and Chinese Scientific Journals Database. The languages were
limited to Chinese and English. Randomized controlled trials were selected by 2
investigators. Analyses were performed using RevMan 5.0 software.
Results: A total of 3139 patients in 4 studies met the inclusion criteria. In those
atients, complete hematologic response and cytogenetic responses showed significant
mprovements in favor of IFN-alfa Ara-C, with complete hematologic response relative
risk (RR) of 1.15 (95% CI, 1.09–1.21), complete cytogenetic response RR of 1.87 (95%
CI, 1.47–2.38), partial cytogenetic response RR of 1.48 (95% CI, 1.25–1.75), and major
cytogenetic response RR of 1.61 (95% CI, 1.42–1.83), respectively. The overall 3-year
survival rate in the IFN-alfa  Ara-C group was 86% compared with 79% in the
IFN-alfa group (RR  1.09; 95% CI, 1.03–1.14). In the other 2 studies, 5-year overall
survival was 69% compared with 63%, respectively (RR  1.08; 95% CI, 1.01–1.15).
However, IFN-alfa and Ara-C involved higher risk of hematologic toxicity, gastrointes-
tinal adverse events, and severe mucositis compared with IFN-alfa monotherapy (RR 
2.63 [95% CI, 1.94–3.56); RR 3.38 [95% CI, 2.28–5.00], and RR 8.84 [95% CI,
3.82–20.46], respectively). Weight loss and skin rash were also observed more frequently
in the combination treatment group (RR  2.00 [95% CI, 1.47–2.73) and RR  3.75
[95% CI, 2.13–6.59], respectively).
Conclusions: In patients with chronic myelogenous leukemia in the chronic
phase, the combination of IFN-alfa  Ara-C demonstrated improved complete
ematologic response, superior cytogenetic responses, and higher rates of 3- and
-year survival than IFN-alfa alone. However, combination therapy is more likely to
ause serious adverse effects. Well-designed studies will be required to determine the
utcomes and adverse effects of the 2 drugs as treatment for patients with chronic
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INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that typically
evolves through 3 clinical phases: chronic, accelerated, and blast crisis. The hallmark
of CML, the Philadelphia (Ph) chromosome, is an abnormally short chromosome 22
that results from a balanced translocation t(9;22)(q34;q11). The translocation leads to
the formation of a hybrid gene BCR/ABL that encodes for the fusion protein
CR/ABL, which results in deregulated tyrosine kinase activity.1 Incidence rates vary
from 0.6 to 2.0 cases per 100,000 inhabitants, increase with age, and are higher in
men than in women.2
Before the advent of imatinib, the principal mode of CML treatment was palliative
hemotherapy, mostly with busulfan and hydroxyurea. Hydroxyurea can achieve a
ematologic response but not a cytogenetic response (CR).3,4 For a minority of
atients who are appropriate candidates with a suitable donor, curative bone marrow
ransplantation can achieve complete molecular remissions and cure,5 even with
ontinuing progress of this approach with unrelated donors, doctors are still greatly
nterested in drug treatment.
Interferon alfa (IFN-alfa) was introduced in the early 1980s but did not become
idely accepted as primary treatment until several randomized studies6–8 showed
hat IFN-alfa monotherapy provided a significant advantage when compared with
onventional chemotherapy such as hydroxyurea and busulfan. Treatment induces a
omplete hematologic response (CHR) of 40% to 80%, a CR of 15% to 58%, a major
ytogenetic response (MCR; ie, Ph 35%) of 30% to 50%, and a complete cytoge-
etic response (CCR; ie, Ph 0%) of 5% to 25%. The median survival rates range from
0 to 90 months. The positive effect of IFN-alfa on survival, mainly in low-risk
atients, was confirmed by a meta-analysis of the randomized trials.9
Cytarabine (Ara-C) is an antimetabolite, isolated from the sponge Cryptothetya
rypta, which is known to possess anti-CML activity.10 Ara-C produced a superior
utcome in patients with CML who have experienced treatment failure with IFN-alfa
nd should be investigated together with IFN-alfa as part of front-line CML therapy.
ombination therapy with Ara-C and IFN-alfa in patients with chronic phase CML
as shown to increase the rate of MCRs and prolong survival compared with
reatment with IFN-alfa alone.11 Continued research into the treatment of patients
ith CML has shown that achievement of a sustained CCR correlates with prolonged
urvival.4,12
The advent and success of imatinib therapy in CML have dramatically changed the
ML therapeutic algorithm. The remarkably rapid and apparently durable control of
ematologic features and the high rate of CR achieved with imatinib used as a single
Open access under the Elsevier OA license.gent suggest that this drug could substantially prolong life.13 However, response to
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Current Therapeutic Researchthe drug varies among patients, and criteria are tentatively suggested for defining
response and nonresponse or response failure. For example, after 5 years of follow-up
in the International Randomized Study of Interferon and STI571, 5% of patients
receiving imatinib withdrew from therapy or crossed over to the IFN-alfa  Ara-C
arm because of adverse events.4 Moreover, many patients in developing countries were
revented from receiving treatment with this targeted therapy drug because of its
igh cost. Notably, IFN-alfa or IFN  Ara-C was considered the best initial
reatment for patients newly diagnosed with CML not eligible for allogeneic stem cell
ransplantation and those who cannot afford the cost of imatinib treatment. In daily
linical practice, physicians often encounter those types of patients, and these en-
ounters are disconcerting for those who work in developing countries. These reports
rovide a summary of the efficacy and safety of IFN-alfa  Ara-C therapy in these
nrelated donor patients or patients who cannot afford the higher cost of imatinib.
We therefore performed a meta-analysis to assess the long-term outcome of CML
atients in the chronic phase who received IFN-alfa  Ara-C compared with those
ho were treated with IFN-alfa monotherapy.
METHODS
Inclusion criteria were as follows: (1) patients diagnosed with CML; (2) CML patients
with chronic phase of the disease, who were found to be positive for the Ph
chromosome; and (3) patients who had not previously been treated with chemother-
apy, including hydroxyurea, busulfan, and IFN-alfa. Excluded patients were those: (1)
with features of accelerated or blast phases of CML; (2) with a history of depressive
illness or another psychiatric disorder or severe hepatic, renal, or cardiovascular
disorders; (3) age 70 years; and (4) who initially failed to respond to tyrosine kinase
inhibitor treatments.
Types of studies included in the analysis were randomized controlled trials (RCTs)
with subgroup meta-analysis; they were included regardless of whether they provided
information about concealment of allocation. Types of intervention analyzed was
IFN-alfa  Ara-C versus IFN-alfa alone. Types of outcome measures examined:
rimary outcome factors, CHRs, CRs, MCRs, CCRs, and PCRs. Three- and 5-year
urvival rates were also assessed. Secondary outcome measures included toxicities and
dverse effects (hematologic toxicity; nausea, vomiting, and diarrhea; mucositis;
eight loss; fever, flu-like syndrome, or both; neurologic symptoms; psychiatric
isorder; and hepatic events).
Literature Search Strategies
We conducted an electronic literature search of the following databases: Cochrane
entral Register of Controlled Trials, PubMed, EMBASE, Chinese Biomedical Da-
abase, China National Knowledge Infrastructure, and Chinese Scientific Journals
atabase. The studies included were written in English or Chinese. The references for
ach study which met the inclusion criteria were also scanned to identify any studies
hat were not included in the initial search. The following search terms were used as
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leukemia AND (chronic myelocytic leukemia OR chronic granulocytic leukemia OR CML).
Data Extraction
The following data were extracted by one reviewer (B.M.) and checked indepen-
ently by the second reviewer (J.H.T.). We used predesigned forms to collected
nformation about the IFN-alfa and Ara-C tested, the population studied (age, sex,
nd underlying conditions), treatment dosages and dosing schedules, the treatment
ffect at 6 months and 1 year, the specific measurement of this intervention (5-year
urvival rate or CRs), and the incidence of adverse effects and mortality according to
auses of death.
Assessment of Methodologic Quality
Study quality was assessed independently by 2 reviewers (L.Y.L. and Y.K.H.) and
iscrepancies were resolved by consensus. RCTs were evaluated by randomization,
ouble-blinding, and withdrawal/follow-up according to the criteria of the Cochrane
andbook for Systematic Reviews of Interventions.14 Allocation concealment was assessed
as adequate, inadequate, or unclear.15
Statistical Methods
We quantitatively pooled the results of individual trials when possible. For
ichotomous data, relative risk (RR) was calculated and used in description of the
esults. For continuous outcomes, a weighted mean difference was calculated when
utcome measurements in all trials were performed on the same scale. A standardized
ean difference was used when the trials were all assessed using the same outcome,
ut the outcome was measured in a variety of ways. Effects were considered statis-
ically significant if P  0.05. A z-test was used as statistically significant to test the
ifferences in treatment effect between groups.16 For each study, the most adjusted
value or RRs, with their 95% CIs, were used.
Heterogeneity was assessed using the 2 test and I2 test. We set the statistical level
of heterogeneity (2 P) at 0.05 and considered an I2 value 50% to indicate
ubstantial heterogeneity.17 We assessed any identified heterogeneity in an effort to
explain it. If we were unable to find an explanation, such a finding was stressed in the
review and highlighted that caution in the interpretation of these data was appro-
priate. When we found that a cause for heterogeneity was apparent and justified a
separate analysis of the studies with a particular characteristic, such analysis was
undertaken and presented. When we found no heterogeneity, the studies were
included in a meta-analysis for the outcomes selected here. A random effects model
was preferred where there was marked heterogeneity (I2  50%), and a fixed effects
model was preferred in other circumstances. Statistical pooling of results was per-
formed using standard meta-analysis software (RevMan 5.0; The Cochrane Collabo-
ration, The Nordic Cochrane Centre, Copenhagen, Denmark). We planned to assess
the possibility of publication bias using the funnel plot method18 for the primary end
oints.
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Description of Studies
The literature searches yielded a total of 1145 potentially relevant citations. The
Figure 1. Study identification and selection process. Flow chart provides numbers of
randomized controlled trials (RCTs) identified, excluded for various reasons, and
included in the systematic review and meta-analysis. VIP  Chinese Scientific
Journals Database; CBM  Chinese Biomedical Database; IFN-alfa  Ara-C 
interferon alfa  cytarabine; CNKI  China National Knowledge Infrastructure.election process is illustrated in Figure 1. The 4 randomized controlled trials19–22
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Ara-C therapy and 1556 were assigned to receive IFN-alfa alone.
Methodologic Quality of Included Studies
The characteristics of the 4 included studies are summarized in the Table. Only
study19 explicitly described the randomization process and involved adequate
llocation concealment with an intention-to-treat analysis. The population sizes in
hese 4 studies ranged from 538 to 1340, and the duration of follow-up ranged from
months to 5 years.
Publication Bias
Overall, there was no apparent asymmetry in the funnel plots (Figure 2) when
valuating our publication bias, and no significant publication bias was detected in
ur meta-analysis.
Assessment of Clinical Effectiveness
All 4 articles reported information on CHR compared between an intervention
roup and a control group. The CHR in the IFN-alfa  Ara-C arm was 68% (1082
f 1583 patients) compared with 60% (927 of 1556 patients) in the IFN-alfa arm.
he summary RR was 1.15 (95% CI, 1.09–1.21). Heterogeneity was not detected
mong these studies (P  0.46; I2  0%).
Figure 3 presents detailed data related to subgroup CR for all 3043 available
articipants in all 4 studies.19–22 Tests of heterogeneity were not significant (CCR,
 0.69, I2  0%; PCR, P  0.54, I2  0%; MCR, P  0.93, I2  0%). CCR
RR (fixed-effect model) was 1.87 (95% CI, 1.47–2.38), PCR RR was 1.48 (fixed-
effect model) (95% CI, 1.25–1.75), and MCR RR was 1.61 (fixed-effect model) (95%
CI, 1.42–1.83); these findings showed statistically significant improvements in favor
of the combination study regimen compared with treatment with IFN-alfa alone.
Figure 4 presents a trend in favor of combination treatment compared with
treatment with IFN-alfa alone. By implementing subgroup analysis, 3-year overall
survival was 86% (548 of 635 patients) compared with 79% (497 of 626 patients) in
2 studies,20,21 with an RR (fixed-effect model) of 1.09 (95% CI, 1.03–1.14); 5-year
verall survival was 69% (626 of 910 patients) compared with 63% (565 of 887
atients) in the other 2 studies,19,22 with an RR (fixed-effect model) of 1.08 (95% CI,
1.01–1.15). No statistical heterogeneity existed in the 2 subgroups (P  0.38, I2 
0%; and 0.61, I2  0% separately).
Secondary Outcome Measures
Three individual trials19,20,22 reported different types and frequency of adverse events
(represented in Figure 5). The combined therapy involved a higher incidence of hema-
tologic toxicity, gastrointestinal adverse events such as nausea, vomiting, and diarrhea,
and severe mucositis (RR [fixed-effect model]  2.63 [95% CI, 1.94–3.56]); RR
[fixed-effect model]  3.38 [95% CI, 2.28–5.00]); and RR [fixed-effect model]  8.84
[95% CI, 3.82–20.46], respectively). The occurrence of weight loss and skin rash was
observed more frequently in the IFN-alfa  Ara-C group compared with the IFN-alfa
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Table. Clinical characteristics and methodologic quality of the included studies.
Study/
Year
No. of
Participants Intervention (dose and schedule)
Outcome Measures Randomization
Allocation
Concealment Blinding
Withdrawal/
Follow-up
IFN-Alfa/
Ara-C IFN-Alfa IFN-Alfa/Ara-C IFN-Alfa
Guilhot
et al,20
1997
360 361 IFN-alfa-2b: initial
dose 5 MU/m2
SC Ara-C: 20
mg/m2 in a
single daily dose
for 10 d SC
IFN-alfa-2b: initial
dose 5 MU/m2
SC
CHR (6 mo) CR (12 mo),
MCR, CCR, PCR SR (3 y)
Adverse effects
Adequate Adequate Not reported Yes, ITT analysis
was performed
Kantarjian
et al,21
2000
275 265 IFN monthly
courses of
cytarabine
IFN CHR (6 mo) CR (12 mo),
MCR, CCR, PCR SR (3 y)
Unclear Unclear Not reported Yes
Baccarani
et al,19
2002
275 263 hrIFN-alfa-2a: 36
IU/d, first 2 wk;
66 IU/d, the next
2 wks; 56 IU/
m2/d SC/IM
LDAC: 40 mg/d
the first 10 d of
each mo
hrIFN-alfa-2a: 36
IU /d, first 2 wk;
66 IU/d, the next
2 wks;56 IU/m2/
d, thereafter,
SC/IM
CHR (6 mo), the time to
achieve CHR CR (12 mo
/24 mo), MCR, CCR,
PCR SR (5 y), its 95% CI
Adverse effects
Unclear Unclear Not reported Yes
Pingoy
et al,22
2003
673 667 LDAC added to
the standard IFN-
alfa protocol
IFN-alfa CHR (6 mo) CR (12 mo),
MCR, CCR, PCR SR (5 y)
Adverse effects
Unclear Unclear Reported Yes
IFN-Alfa Ara-C interferon alfa cytarabine; CHR complete hematologic response; CR cytogenetic response; MCRmajor cytogenetic response;
CCR  complete cytogenetic response; PCR  partial cytogenetic response; SC  subcutaneously; SR  survival rate; hr  human recombinant; IM 
intramuscularly; ITT  intention-to-treat analysis; LDAC  low-dose cytarabine.
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R. Chen et al.alone group (RR [fixed-effect model]  2.00 [95% CI, 1.47–2.73] and RR [fixed-effect
model] 3.75 [95% CI, 2.13–6.59], respectively). However, other adverse effects—such
s fever, flu-like syndrome or both, neurologic symptoms, psychiatric disorder, and
epatic events—manifested no statistical differences. Heterogeneity was not detected
Figure 2. Funnel plots of (A) complete hematologic response (CHR); (B) cytogenetic
response (CCR  complete cytogenetic response; PCR  partial cytogenetic
response; MCRmajor cytogenetic response); and (C) survival rate (SR). RR
relative risk.mong subgroups except with respect to weight loss (P  0.11; I2  55%).
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Adult patients with chronic-phase CML were investigated in this meta-analysis,
which found that use of the IFN-alfa  Ara-C regimen resulted in a statistically
ignificant advantage in CHR rate.
Figure 3. Randomized controlled trials of complete hematologic response (CHR). IFN-
alfa Ara-C interferon alfa cytarabine; M-HMantel-Haenszel method; RR
relative risk. The I2 statistic describes the percentage of total variation across
studies that is due to heterogeneity rather than chance.
Figure 4. Randomized controlled trials of cytogenetic response. IFN-alfa  Ara-C  inter-
feron alfa  cytarabine; CCR  complete cytogenetic response; PCR  partial
cytogenetic response; MCR  major cytogenetic response; RR  relative risk.
The I2 statistic describes the percentage of total variation across studies that
is due to heterogeneity rather than chance.
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as found in MCR, CCR and PCR values. This finding appears to be in accordance with
ontrolled clinical clamp studies,23,24 which demonstrated in a multivariate analysis that
a CR achieved with IFN-alfa  Ara-C was independently associated with improved
survival. In terms of overall survival rate, the results obtained from this meta-analysis were
comparable in both the IFN-alfa Ara-C arm and IFN-alfa monotherapy arm. However,
although the results discussed here came from only 4 RCTs, we reported a statistically
significant benefit in CHRs, CRs, and 3- or 5-year survival rates, which could be used to
determine clinical significance for the chronic phase of CML.
Throughout our extensive literature search, we did not identify any trials involved
in the treatment of accelerated phase or blast crisis patients for comparison of the
combination therapy versus single IFN-alfa only. Ferrajoli et al25 reported that
atients with late chronic and accelerated phase CML benefit from combined IFN-
lfa  ARA-C treatment and achieve hematologic and cytogenetic responses not
btained during previous treatment without being exposed to undue toxicity. There-
ore, it is unknown whether the use of IFN-alfa  Ara-C will attain the same or
igher cytogenetic remission results in the accelerated phase or blast crisis.
The frequency of adverse events of the 2 drugs differed significantly between the
ombination arm and the IFN-alfa arm, which suggests that combination treatment
an cause more adverse effects for patients with CML. A total of 80% of the studies
rovided at least some information on adverse events. Overall, the reported frequency
nd type of adverse events (local site reactions and hematologic toxicity) and discon-
inuation rate were comparable between the combination arm and the IFN-alfa alone
rm. Data on the incidence of serious adverse events episodes are limited. In terms of
ematologic toxicity, adequate measurements indicators include leukopenia, neutro-
Figure 5. Randomized controlled trials of overall survival rate (SR). IFN-alfa  Ara-C 
interferon alfa  cytarabine; RR  relative risk. The I2 statistic describes the
percentage of total variation across studies that is due to heterogeneity rather
than chance.enia, and thrombocytopenia. There was only 1 original RCT20 that specified the
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Current Therapeutic Researchabsolute level of thrombocytopenia, which in the IFN  Ara-C arm was 2 times
that observed after treatment with IFN alone (20 vs 8). Patients who received
combination treatments exhibited a higher occurrence of nonhematologic toxicity,
including nausea, vomiting, diarrhea, mucositis, weight loss, and discomfort with an
additional subcutaneous injection. We were not able to identify increased severity or
frequency of adverse effects caused by IFN-alfa or Ara-C because patients were
administered different dosages of 1 or 2 drugs and subjected to varying medication
regimens. IFN-alfa was administered in all study protocols with a wide dose range
between 5 MU/m2 and 5 6IU/m2. Daily doses of Ara-C in the studies discussed here
range from an absolute dose of 20 mg to 40 mg/m2.
Limitations and Implications of Research
This review summarizes the large body of literature comparing the effects of
FN-alfa  Ara-C versus IFN-alfa alone for patients with CML in the chronic phase.
owever, there are several limitations that must be addressed. First, this effort
ncluded studies written only in English or Chinese, which may not be representative
f the entire literature available. We should be particularly concerned about publi-
ation bias in settings that do not foster English or Chinese language use. The risk
f having missed or overlooked trials in this setting was substantial, as assessed by
ests for publication bias and funnel plot. The analysis revealed no obvious publica-
ion bias in our study, which suggests that publication bias was unlikely to be an
mportant factor. However, the limited number of trials in each of the comparisons
akes assessment of publication bias difficult. The results may be affected due to the
imited number of studies included. Second, a common shortcoming of the quality in
he trials was the inadequate description of the randomization and blinding proce-
ures, as well as the absence of intention-to-treat analyses. Third, other important
eaknesses were the very poor description of dropouts and of harm-related issues (eg,
nly 1 trial20 reported all of the causes of death for each study arm). Finally, outcome
ata from the original publication could not be included in the analysis for meth-
dologic reasons (eg, no separate analysis for 3- and 5-year survival rates provided).
nfortunately, communications with the authors did not substantially improve the
ata quality. Few authors submitted the original data that we requested. Addition-
lly, another concern was that patients enrolled in this study admitted to receiving
llogeneic bone marrow transplantation or autologous stem cell transplantation at any
ime that they had appropriate donors, so loss to follow up was inevitable during the
ntire course of treatment.
Based on the limits of this meta-analysis, future research efforts should focus on
arge, well-designed studies. Long-term follow-up data from the first- and second-line
FN- or Ara-C–based trials are critical to determine the effect on survival, duration
f response, and development of resistance. Research is also needed into specific
ubgroups, such as accelerated or blast phase of CML patients, the elderly,
hildren, or those eligible for bone marrow transplantation. Further investigation
f IFN-alfa  Ara-C on quality of life is important, especially in terms of evaluating
ocietal values. More detailed economic studies are also required to aid appraisal of the
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provide cost-effective guidelines.
CONCLUSIONS
In patients with the chronic phase of CML, the available evidence from the literature
was sufficient to make several conclusions. Ara-C combined with IFN-alfa signifi-
cantly improved CHR and CR rates as well as prolonged 3- and 5-year survival
compared with IFN-alfa alone. Combination therapy was more likely to cause serious
adverse effects, and the reported methodologic quality of included studies was
generally poor to intermediate. Therefore, from this meta-analysis, the regimen of
IFN-alfa  Ara-C may be the first choice for CML patients who live in developing
ountries, given the superiority of imatinib. Given further safety concerns, we need
long-term follow-up study enrolling large numbers of patients who use combination
reatment. Also needed are well-designed studies of accelerated or blast phase diseases
o determine the safety profile for both these drugs.
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